Related Experiment Video
Updated: Aug 17, 2025
Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis
Takanori Sano1, Kazuhiro Kikuta1, Tetsuya Takikawa1
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan.
Background/Objectives:
Proper assessment of disease activity and prediction of relapse are crucial for the management of autoimmune pancreatitis (AIP). The M-ANNHEIM-AiP-Activity-Score (MAAS) has been proposed to determine disease activity and predict relapse in German and Swedish patients with AIP. MAAS is calculated using six categories: pain report, pain control, exocrine insufficiency, endocrine insufficiency, imaging, and complications. This study aimed to clarify the usefulness of MAAS to predict relapse in Japanese patients with type 1 AIP.
Methods:
We retrospectively analyzed 117 patients with type 1 AIP undergoing initial and maintenance steroid treatments at our institute between April 2006 and March 2021. AIP was diagnosed according to the Japanese Diagnostic Criteria for AIP 2018. We examined the association of MAAS with relapse during and after maintenance treatment.
Results:
MAAS (median, 8 points) at the start of the initial treatment was reduced after treatment (median, 4 points; P < 0.001). A MAAS ≥11 points at the start of the initial treatment was associated with relapse. The initial treatment-induced reduction of MAAS<60% was more frequent in patients with relapse (75.0%) than in patients without relapse (37.6%; P = 0.007). MAAS at the start of maintenance treatment was higher for patients with relapse (median, 5 points) than that for patients without relapse (median, 4 points; P = 0.007). MAAS ≥4 points at the start of maintenance treatment was associated with subsequent relapse.
Conclusions:
MAAS is useful for predicting relapse in patients with type 1 AIP undergoing maintenance therapy.
Insights
The M-ANNHEIM-AiP-Activity-Score (MAAS) effectively predicts relapse in Japanese patients with autoimmune pancreatitis (AIP) type 1. Higher MAAS scores at the start of initial or maintenance therapy indicate increased relapse risk.
Area of Science:
- Gastroenterology
- Immunology
- Clinical Medicine
Background:
- Autoimmune pancreatitis (AIP) management requires accurate disease activity assessment and relapse prediction.
- The M-ANNHEIM-AiP-Activity-Score (MAAS) assesses AIP activity and relapse risk in European cohorts.
- This study evaluates MAAS utility in Japanese patients with type 1 AIP.
Purpose of the Study:
- To determine the effectiveness of the MAAS in predicting relapse in Japanese patients with type 1 AIP.
- To assess the association between MAAS scores and relapse during and after steroid treatment.
Main Methods:
- Retrospective analysis of 117 Japanese patients with type 1 AIP treated between 2006 and 2021.
- Diagnosis confirmed using the Japanese Diagnostic Criteria for AIP 2018.
- Examination of MAAS score correlations with relapse events during and post-maintenance steroid therapy.
Main Results:
- MAAS scores significantly decreased after initial treatment (median 8 to 4; P < 0.001).
- MAAS ≥11 at initial treatment start and MAAS ≥4 at maintenance start predicted relapse.
- Lower initial treatment-induced MAAS reduction (<60%) was linked to higher relapse rates (75.0% vs 37.6%; P = 0.007).
Conclusions:
- The MAAS is a valuable tool for predicting relapse in type 1 AIP patients.
- MAAS aids in managing patients undergoing maintenance therapy for autoimmune pancreatitis.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Acute Pancreatitis II: Clinical Manifestations and Management